| 02.10 22:44 | dpa-AFX: Arcus Announces Clinical Trial Collaboration With AstraZeneca To Evaluate Casdatifan |
| 02.10 22:13 | dpa-AFX: *ARCUS, ASTRAZENECA TO EVALUATE COMBINATION MOLECULES FOR CLEAR CELL RENAL CELL CARCINOMA TREATMENT |
| 01.10 13:05 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO:ENHERTU GRANTED PRIORITY REVIEW IN US FOR HER2-LOW/HER2-ULTRALOW METASTATIC BREAST CANCER |
| 01.10 08:29 | dpa-AFX: Daiichi Says Enhertu Gets Priority Review In US In HER2 Low/HER2 Ultralow Metastatic Breast Cancer |
| 01.10 08:05 | dpa-AFX: *DAIICHI: ENHERTU GRANTED PRIORITY REVIEW IN U.S. FOR HER2 LOW OR HER2 ULTRALOW METASTATIC BREAST CANCER |
| 26.09 08:22 | dpa-AFX: AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer |
| 26.09 08:03 | dpa-AFX: *ASTRAZENECA'S TAGRISSO APPROVED IN US FOR PATIENTS WITH UNRESECTABLE, STAGE III EGFR-MUTATED LUNG CANCER |
| 26.09 08:02 | dpa-AFX: *ASTRAZENECA SAYS TAGRISSO APPROVED IN THE US FOR PATIENTS WITH UNRESECTABLE STAGE III LUNG CANCER |
| 25.09 08:26 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 25.09 08:26 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 23.09 18:04 | MÄRKTE EUROPA/Erholungstag - Commerzbank mit Achterbahnfahrt |
| 23.09 16:04 | MÄRKTE EUROPA/Erholungstag - Euro nach PMIs etwas leichter |
| 23.09 13:12 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 23.09 13:12 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 23.09 12:47 | MÄRKTE EUROPA/Erholungstag - Euro von schwachen PMIs belastet |
| 23.09 10:25 | Rückschlag für Astrazeneca mit Krebsmedikament in Phase-3-Studie |
| 23.09 08:47 | dpa-AFX: AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance |
| 23.09 08:41 | dpa-AFX: CHMP Recommends AstraZeneca's Fasenra For Approval In Eosinophilic Granulomatosis With Polyangiitis |
| 23.09 08:12 | dpa-AFX: *ASTRAZENECA SAYS TROPION-BREAST01 PHASE III TRIAL FAILS TO ACHIEVE STATISTICAL SIGNIFICANCE IN FINAL OVERALL SURVIVAL |
| 23.09 08:08 | dpa-AFX: *ASTRAZENECA'S FASENRA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS |
|
|
